Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Coronavirus Disease 2019 and Pituitary Apoplexy: A Single-Center Case Series and Review of the Literature

Rafael Martinez-Perez1, Michael W. Kortz1, Benjamin W. Carroll2, Daniel Duran2, James S. Neill3, Gustavo D. Luzardo2, Marcus A. Zachariah2

BACKGROUND: Pituitary apoplexy (PA) is a rare, but life-threatening, condition characterized by pituitary infarction and hemorrhage, most often in the setting of a preexisting adenoma. The risk factors and mechanisms associated with PA are poorly understood. Although neurovascular manifestations of coronavirus disease 2019 (COVID-19) infection have been documented, its association with PA has not yet been determined.

METHODS: From a prospectively collected database of patients treated at a tertiary care center for pituitary adenoma, we conducted a retrospective medical record review of PA cases during the COVID-19 pandemic from March 2020 to December 2020. We also conducted a literature review to identify other reported cases.

RESULTS: We identified 3 consecutive cases of PA and concomitant COVID-19 infection. The most common symptoms at presentation were headache and vision changes. The included patients were successfully treated with surgical decompression and medical management of the associated endocrinopathy, ultimately experiencing improvement in their visual symptoms at the latest follow-up examination. COVID-19 infection in the perioperative period was corroborated by polymerase chain reaction test results in all the patients.

CONCLUSIONS: With the addition of our series to the literature, 10 cases of PA in the setting of COVID-19 infection have been confirmed. The present series was limited in its ability to draw conclusions about the relationship between these 2 entities. However, COVID-19 infection might represent a risk factor for the development of PA. Further studies are required.

INTRODUCTION

As of May 2021, the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected 192 countries and left >3 million people dead.1 Although primarily a respiratory disease, the coagulopathic, inflammatory, and neurologic manifestations of COVID-19 infection have been documented and represent potential therapeutic targets to limit the morbidity and mortality.2-5 Neurologic sequelae, even among those without severe pulmonary infection, include impaired consciousness and cognition, seizure, neurovascular ischemia, and intracranial hemorrhage.6-8

Pituitary apoplexy (PA) is a life-threatening condition characterized by intraparenchymal hypophyseal infarction and/or hemorrhage, often in the setting of preexisting pituitary adenoma.9 It is relatively rare in the general population, with symptomatic cases occurring in ~10% of those with pituitary adenoma.10 Patients will typically present with sudden headache, vision changes, and endocrinopathy.11 PA in association with an underlying COVID-19 diagnosis has been reported; however, the presence of confounding variables (i.e., concomitant anticoagulation therapy and/or the predilection of COVID-19 for critically ill patients) has
limited the ability to draw conclusions of causation.\(^\text{13}\) Nevertheless, the propensity for COVID-19 to propagate microvascular ischemia, such as occurs with PA, has been characterized and represents a logical connection between the 2 entities.\(^\text{5,4,15,16}\)

In the present report, we have described 3 consecutive patients with PA, minimal comorbidity, and concurrent COVID-19 infection in the perioperative period who had been treated at our tertiary care center. In the context of a literature review, we have discussed the potential clinical and pathophysiologic relationship between these 2 conditions.

METHODS

We performed a retrospective case series of patients who had been admitted to a single tertiary care hospital for neurosurgical management of PA from March 2020 to December 2020. Special attention was given toward the temporal relationship between the symptom onset of PA and the COVID-19 diagnosis during or shortly before admission. The medical records and imaging examinations were retrospectively reviewed. These data were presented to the institutional review board of our institution, which waived the need for patient informed consent owing to the anonymized retrospective case-series design.

To strengthen the discussion of a potential relationship between PA and COVID-19, we also conducted a literature review. A search of the PubMed and Google Scholar databases was performed on May 11, 2021. The search terms included combinations of 1) “pituitary apoplexy,” “pituitary hemorrhage,” and “hypopituitarism”; and 2) “COVID-19,” “coronavirus,” and “SARS-CoV-2.” Case reports and/or studies that had reported on the relationship between COVID-19 and PA or the occurrence of abrupt hypopituitarism were of particular interest.

RESULTS

Three patients (2 women and 1 man; average age, 54 ± 2 years) had been treated for PA during the 10-month study period. All 3 patients had also been diagnosed with confirmed COVID-19 during or shortly before their admission, with no patient with PA presenting to our institution without concomitant COVID-19. These patients did not have any intracranial lesions other than PA, had not experienced any additional obvious neurologic complications from the COVID-19 infection, and had not been receiving anticoagulation therapy before their PA diagnosis. All relevant laboratory values, such as D-dimer, fibrinogen, platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT), were within the normal limits for all 3 patients. Two of the patients had a medical history of hypertension and obesity. However, no pertinent history for a systemic autoimmune disease (i.e., endotheliitis or vasculitis) was described for any of the 3 patients. All 3 patients had presented with vision dysfunction and headache, in addition to the respiratory symptoms of their viral pneumonia. Using the 2007 American Thoracic Society guidelines for community-acquired pneumonia, all 3 patients met the criteria for nonsevere pulmonary disease.\(^\text{12}\) The cases of our patients are described in the next sections.

Patient 1

A 54-year-old woman was transferred to our center from an outside hospital with the complaint of a holocranial headache that had started 1 week previously. The patient reported that 2 days earlier, the headache had acutely worsened, with a new focal retroorbital component. She also noted blurry vision in her right eye 1 day later but denied frank diplopia. On neurologic examination, she was aware and alert, and the cranial nerve findings were unremarkable. Her visual acuity was subjectively normal on the left. However, she could only perceive light on the right. Magnetic resonance imaging (MRI) demonstrated a hemorrhagic mass in the region of an enlarged sella turcica, along with suprasellar extension, suggesting a previously undetected tumor. PA was suspected within the parenchyma of a preexisting adenoma.

During her workup, the patient had endorsed contact with her grandson ∼1 week earlier coincidental with her headache onset. Her grandson was subsequently confirmed to be positive for COVID-19 infection. Because of this history and her symptoms, strict COVID-19 precautions and isolation measures were started for the patient. Subsequent polymerase chain reaction (PCR) test results were positive for COVID-19. The patient underwent resection of her sellar mass on the day of presentation via right frontoparietal craniotomy without complications.

Her headache had resolved shortly after the procedure. At the 1-month follow-up, her right visual acuity dysfunction had significantly improved, from only light perception preoperatively to 20/50 and right hemianopsia. Postoperatively, the patient required substitutive treatment with hydrocortisone, levothyroxine, and desmopressin. Pathologic examination confirmed a hemorrhagic null cell adenoma. The imaging studies are presented in Figure 1.

Patient 2

A 56-year-old obese man with a history of hypertension and hypothyroidism had been transferred from an outside hospital with the complaint of a 1-week history of headache. Initially, he was prescribed analgesia, received fluids, and was discharged home. However, owing to his headache’s persistence and the new onset of binocular diplopia, he presented to his primary care physician. At that time, computed tomography of the head revealed a sellar hemorrhagic mass, and he was subsequently transferred to our tertiary care center.

On arrival, the neurologic examination revealed altered mental status and complete third and fourth cranial nerve palsy. No visual deficits were objectively assessed. However, given his altered mental status, MRI was promptly ordered, which confirmed a sellar hemorrhagic lesion with invasion of the right cavernous sinus. After initial stabilization, further questioning revealed that the patient had begun experiencing chills and myalgias ∼10 days before admission. No confirmed community exposure was identified; however, PCR testing demonstrated positivity for COVID-19 infection. Precautions were taken, and the patient was isolated in accordance with our institutional protocol. He subsequently underwent endonasal transsphenoidal microscopic resection of the sellar mass on the day of admission without complications.

The patient’s postoperative course was uneventful, and he was discharged home on the second postoperative day with no evidence of hyponatremia or diabetes insipidus, although he did
require hydrocortisone and levothyroxine supplementation. At the 6-week follow-up visit, the neurologic examination revealed complete resolution of his third and fourth cranial nerve palsies. The final pathologic examination demonstrated necrotic and hemorrhagic tissue within a lactotroph-type pituitary adenoma, confirming the diagnosis of PA. The imaging studies are presented in Figure 2.

Patient 3
A 52-year-old obese man with a history of hypertension had presented to the emergency department complaining of acute headache. The patient endorsed that during the previous year, he had been experiencing progressive peripheral vision loss that had started in his left eye and had begun to involve the right eye after a few months. He also reported decreased libido and impotence for ~2 years before his presentation. The patient was then evaluated by ophthalmology, who confirmed his bitemporal hemianopsia. These findings prompted MRI with a pituitary protocol, which revealed a sellar mass with a significant hemorrhagic component, sellar remodeling, and upward displacement of the optic chiasm. At follow-up 3 days later, the patient reported his headaches were increasing in intensity with no improvement in his visual findings.
symptoms. He subsequently was scheduled for elective endoscopic transsphenoidal resection.

The patient’s preoperative pituitary laboratory test results demonstrated central hypothyroidism, hypogonadism, low insulin-like growth factor-1, and low-to-normal cortisol levels. His surgery was uneventful. Intraoperatively, a predominantly liquefied hemorrhagic mass was identified with necrotic tissue, especially along the posterior aspect of a markedly expanded sella. One day after surgery, the patient began to experience a cough and shortness of breath, accompanied by low-grade fever and chills. PCR testing for COVID-19 infection was positive.
After surgery, hydrocortisone therapy was begun for hypocortisolism, and the patient was discharged home on postoperative day 3 with no evidence of hyponatremia or diabetes insipidus. Postoperatively, the patient made an excellent recovery with complete reversal of his visual disturbances. Pathologic examination confirmed a lactotroph pituitary adenoma. The imaging studies are presented in Figure 3.

**Literature Review**

We identified 9 cases of pituitary dysfunction within the setting of suspected SARS-CoV-2 infection reported since March 2020. One pediatric patient, a 9-year-old girl had developed a suprasellar nongerminomatous germ cell tumor and asymptomatic COVID-19. Another patient, a 28-year-old woman, had been confirmed to have PA, although it was not clear whether the patient had ever contracted COVID-19. She had demonstrated spontaneous resolution of her PA after a surgical delay. Although of interest and relevance to our study, these 2 cases were subsequently excluded. The cases of the 7 remaining patients are presented with the cases of our 3 patients in Table 1.

**DISCUSSION**

PA is a clinical emergency. Although neurologic manifestations of COVID-19 have been reported, the relationship between COVID-19 and PA has yet to be established. We have reported 3 confirmed cases of PA and concomitant COVID-19 infection, providing suggestive evidence of an association between the 2 entities.

**Epidemiology and Pathophysiology**

PA is rare, with a prevalence of 6.2 per 100,000 persons, with symptomatic PA occurring in ~2%–12% of patients with adenoma. Most patients affected range in age from 37 to 58 years, and men are nearly twice as likely to present with PA than are women. It is generally accepted that PA is a consequence of spontaneous intrasellar hemorrhage and/or infarction of the hypophysis, typically in the setting of a preexisting adenoma. Although its exact mechanism is not fully understood, several predisposing factors have been suggested. In a 2015 review of 1202 cases, Briet et al. reported that angiography, surgery (i.e., cardiac, orthopedic, other), closed head trauma, dynamic testing (i.e., dexamethasone suppression), suprasellar macroadenoma.

![Figure 3. Imaging studies for patient 3. Preoperative (A) coronal T1-weighted contrast-enhanced, (B) sagittal T1-weighted contrast-enhanced, and (C) axial T1-weighted contrast-enhanced magnetic resonance imaging scans and (D) axial computed tomography scan demonstrating a sellar lesion with suprasellar extension and a fluid level compatible with intratumoral subacute bleeding. Postoperative (E) coronal T1-weighted contrast-enhanced, (F) sagittal T1-weighted contrast-enhanced, and (G) axial T1-weighted contrast-enhanced magnetic resonance imaging scans demonstrating decompression of the optic chiasm with residual tumor extending into the right cavernous sinus.](image-url)
extension, pregnancy, chronic hypertension, increased intracranial pressure, and therapy with dopamine or gonadotropin-releasing hormone agonists have all been proposed. Common etiologic themes leading to PA include acute derangements in blood pressure (especially hypotension), anticoagulation therapy, and greater metabolic demands in the setting of chronically stressed
hypophyseal vasculature. In contrast to the hypophyseal portal system of the normal pituitary gland, pituitary adenomas derive most of their blood supply from direct arterial branches. As the sellar mass grows, the vascular reservoir for the adenoma decreases amidst a reduction in angiogenesis. Furthermore, the normal endothelial organization of the capillary bed has been observed to be replaced by an arteriolar arrangement in the setting of an adenoma, limiting erythrocyte migration into the tumor. Postmortem histologic brain examinations of patients with COVID-19 revealed a propensity for hypoxic brain damage and neuroinflammation. These 2 processes together might explain endothelial dysfunction in the hypophyseal vasculature in the occurrence of PA associated with COVID-19 infection.

Previous studies have described a syndrome of hypopituitarism in the presence of flavivirus or bunyavirus infection. This appears to result from complications of viral tropism for the pituitary gland and ischemic and/or hemorrhagic sequelae from vascular damage. A similar pathophysiologic mechanism has been proposed for PA in the setting of COVID-19 infection amid accumulating evidence suggesting that COVID-19 targets the nervous system. The reported rates of stroke in patients with COVID-19 infection have ranged from 0.9% to 5.7%, and the incidence of venous thromboembolism has been as high as 36% in patients admitted to the intensive care unit. In a study of 32 critically ill patients with COVID-19, 8 (25%) had experienced severe central nervous system involvement. Similarly, intracranial hemorrhage or cerebral microbleeding events have been reported in ≤22% of critically ill patients. Patients with COVID-19 infection who experience stroke are more likely to be younger and to have a higher National Institutes of Health Stroke Scale score at admission. COVID-19 has shown affinity for the angiotensin-converting enzyme-2 (ACE-2) receptor on the host cells of the central nervous system and vasculature. This leads to cellular internalization of the virus, where COVID-19 down-regulates ACE-2 receptors and leads to oxidative stress, vasodilation, neuroinflammation, and thrombogenesis. Vascular dysautoregulation and microischemia subsequently ensue.

With the addition of our series, we found 10 cases of PA concurrent with COVID-19 infection reported in the literature. In all but 1 of these patients, a preexisting macroadenoma was identified. Bordes et al reported sellar hemorrhage without an underlying tumor, which could be secondary to the relatively older age of the patient and their comorbid hypertension. Hypertension was similarly seen in 2 of our patients, representing a potential risk factor for PA in the setting of acute respiratory infection, regardless of macroadenoma presence or size. Although the increased risk of coagulopathy associated with COVID-19 infection is related to elevated fibrinogen and D-dimer levels, mild thrombocytopenia, and normal or mild prolongation of PT and aPTT, the laboratory values for all 3 of our patients were within normal limits. This might prompt the
initiation of unfractionated or low-molecular-weight heparin, representing another potential risk factor for PA. However, none of our patients had received anticoagulation therapy; thus, PA could represent the natural history of a predisposed pituitary adenoma patient susceptible to COVID-19 viral tropism, thrombocytopenia, coagulopathy, and abrupt blood pressure changes even without concerning laboratory values.

In accordance with the Bradford-Hill criteria, which assess the epidemiological evidence of causality between 2 phenomena, our findings suggest the association between PA and COVID-19, given that ours is the largest consecutive series to date. Additionally, the consistency of our results (all patients treated at 1 neurosurgery department) and the absence of clear predisposing factors, other than hypertension and obesity in 2 patients (specificity), might improve confidence in our evidence. The other risk factors for PA, including head trauma, intracranial hypertension, radiotherapy, pregnancy, and anticoagulation, were not present in any of our 3 patients. Temporality is also important to establish causality and was met in our report, especially for patients 1 and 2. These 2 patients had had a positive COVID-19 test within 1 month before their admission for PA. Patient 3 had tested positive for COVID-19 at 4 days after the diagnosis of PA, which warrants extra caution in concluding a causal relationship. In contrast, however, considering that the mean incubation time for COVID-19 time is 5 days, this patient could have already been infected and asymptomatic when he experienced symptoms relative to the pituitary infarction. Additionally, of the reported patients with PA had had nonsevere pulmonary infections, which could also support the idea that PA can manifest regardless of COVID-19 severity or symptoms. This relationship also requires confirmation.

Management and Outcomes
Patients who present with symptoms of PA and suspected COVID-19 infection or in areas of high community spread should undergo nasopharyngeal reverse transcription PCR and be isolated in accordance with institutional and public health authority standards. Evidence has demonstrated the presence of SARS-CoV-2 in the cerebrospinal fluid, which might raise suspicion about the viral relationship and bleeding diathesis. Reverse transcription PCR testing of the cerebrospinal fluid could illuminate the presence of direct invasion of the virus into the central nervous system and should be considered in the routine care of patients with PA and confirmed COVID-19 infection. If immediate surgery is required, pituitary management protocols should be initiated to protect the treating staff and limit viral transmission. For nonemergent PA, patients should be treated conservatively where possible and monitored closely and undergo surgery when their COVID-19 infection has resolved.

From a PA management perspective, it is worthwhile to highlight the importance of monitoring the fluid and electrolyte balance and correcting pituitary hormone deficiencies. Of particular interest is weighing the benefits and risk of anticoagulation and antiplatelet therapy when concerned for thrombosis in patients with pituitary macroadenoma and COVID-19, especially in the presence of laboratory evidence of derangements in D-dimer, fibrinogen, platelets, and PT and aPTT. Preemptive surgery might be warranted in these cases. Ibuprofen has also been associated with an increased number of ACE-2 receptors within the cell membrane, which might increase the infectivity of SARS-CoV-2. Thus, clinicians should be wary of administering ibuprofen to patients with COVID-19 and patients with known macroadenoma until COVID-19 has been ruled out, considering that headache is a common presenting symptom of PA. Once the patient has been stabilized, the decision to perform surgery depends heavily on the patient’s visual status. PA is generally considered a surgical emergency when associated with acute visual deterioration. However, some patients have experienced spontaneous visual improvement with conservative corticosteroid therapy, fluid resuscitation, and hormonal supplementation. We attempted conservative management for 1 of our patients (patient 2), given the subacute progression of his visual symptoms. However, his vision did not improve after a short interval of observation, which prompted surgical resection.

Surgery can be performed via a transphenoidal or transtemporal approach, which should be determined by the morbidity of the individual patient and how it relates to COVID-19 infection. A theoretically increased risk exists of intraoperative COVID-19 transmission during endoscopic transphenoidal surgery secondary to viral particle aerosolization, and the risk should be considered in the center-dependent protocols to protect healthcare staff. In June 2020, Fleseriu et al. and the Professional Education Committee of the Pituitary Society for Pituitary Surgery recommended systematically triaging pituitary patients for the severity of presentation, querying for COVID-19 symptoms, screening for COVID-19 infection via nasopharyngeal swab and chest radiography, and isolation for 2 weeks before surgery. In emergent cases such as PA, which cannot be deferred, full personal protective equipment for all treating clinicians should be worn and the use of a transcranial approach considered. Ultimately, however, little evidence is available that iatrogenic nasopharyngeal aerosolization of SARS-CoV-2 occurs; thus, treating physicians should continue to follow location-specific government- and institution-dependent protocols for surgical management of pituitary pathology. For our series, the transcranial route was chosen for patient 1, primarily to rapidly decompress the third cranial nerve and address the tumor’s lateral expansion. The selection of the approach for all our patients was ultimately determined primarily by surgeon preference, in line with our hospital’s protocol.

Ultimately, clinical morbidity and mortality should represent the outcomes of interest in these patients, whether due to sequelae of their PA or other COVID-19–related manifestations. Although the short-term outcomes, such as endocrinopathy, opthalmoplegia, respiratory dysfunction, and subsequent hospital readmission, are important for these patients and have been noted in the few cases reported thus far, the long-term prognosis remains to be elucidated. These concerns, along with systems-based outcomes, represent potential inflection points for clinical decision-making among pituitary surgery teams.

Study Limitations
Our study had some limitations. Most importantly, its descriptive nature and the small sample size prevented definitive conclusions regarding the true relationship between PA and COVID-19.
19, especially temporally with patient 3. We were similarly unable to compare our 3 patients with a control group owing to unavailable data, which also prohibited a statistical analysis. We also could not take sequences, such as gradient echo sequences, except for in patient 1, during the prospective MRI studies, which would have been useful. The 3 cases were diagnosed at a single center, which could have resulted in historical, confirmation, and design biases.

Future Perspectives
Although the relationship between PA and COVID-19 remains controversial, we believe that our study has provided necessary and relevant preliminary data. With the pandemic still significantly affecting multiple countries, multi-institutional clinical studies might improve the neurosurgical and critical care treatment of these patients. In the long term, the pathogenesis of PA remains to be fully determined. Given the microvascular manifestations of COVID-19, this might represent an opportunity to conduct translational work postmortem and in animal models to determine how patients with pituitary adenoma progress to infarction and/or hemorrhage. Regarding the radiographic diagnosis, when patients have been confirmed to have COVID-19 before their admission for PA, we recommend MRI with a pituitary protocol and gradient echo sequences, which can detect even very minor differences in signal homogeneity.43 This could more effectively guide COVID-19 and PA management and strengthen the confidence of an association between these 2 pathologies.

CONCLUSIONS
With the addition of our 3-patient case series, 10 cases of PA in the setting of confirmed COVID-19 infection have been reported. These cases suggest a relationship between these 2 highly morbid conditions. Molecular downregulation of cellular ACE-2 receptors, vascular dysautoregulation, abrupt hypotension, and coagulopathy could, together, propagate pituitary infarction and hemorrhage, with the presence of a pituitary macroadenoma representing a likely risk factor. Comparative studies are still required to connect these two conditions on a pathophysiology basis. However, until then, COVID-19 should be considered a possible risk factor for PA and management adjusted accordingly.

CRediT AUTHORSHIP CONTRIBUTION STATEMENT
Rafael Martinez-Perez: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Supervision, Visualization, Writing - original draft.
Benjamin W. Carroll: Resources.
Marcus A. Zacharia: Funding acquisition.
James S. Neill: Resources.
Gustavo D. Luzardo: Funding acquisition.

REFERENCES
1. Johns Hopkins University of Medicine. Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/. Accessed May 11, 2021.
2. Carod Artal FJ. Complicaciones neurológicas por coronavirus y COVID-19. Rev Neurrol. 2020;79:312.
3. Yao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. Jama Neurol. 2020;77:685.
4. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2269-2270.
5. Chan NC, Weitz JI. COVID-19 coagulopathy, thrombosis, and bleeding. Blood. 2020;136:581-583.
6. Dogra S, Jain R, Cao M, et al. Hemorrhagic stroke and anticoagulation in COVID-19. J Stroke Cerebrovasc Dis. 2020;29:104984.
7. Jain R, Young M, Dogra S, et al. COVID-19 related neuroimaging findings: a signal of thromboembolic complications and a strong prognostic marker of poor patient outcome. J Neurol Sci. 2020;414:116933.
8. Vattoth S, Abdelhady M, Alsoub H, Own A, Elsotouhy A. Critical illness-associated cerebral microbleeds in COVID-19. Neuroradiol J. 2020;33:374-378.
9. Barkhoudarian G, Kelly DF. Pituitary apoplexy. Neurosurg Clin N Am. 2019;30:457-463.
10. Biett G, Salezze S, Bonneville J-F, Laws ER, Chanson P. Pituitary apoplexy. Endor Rev. 2015;36:622-643.
11. Turgut M, Ozsunar Y, Basak S, Guney E, Kir E, Meteoglu I. Pituitary apoplexy: an overview of 186 cases published during the last century. Acta Neurochir. 2020;152:749-761.
12. Frazza S, Allora C, Castellino L, di Filippo L, Loli P, Giustina A. COVID-19 and the pituitary. Pituitary. 2021;24:485-491.
13. Melmed KR, Cao M, Dogra S, et al. Risk factors for intracerebral hemorrhage in patients with COVID-19. J Thromb Thrombolysis. 2021;51:95-100.
14. Sharifi-Razavi A, Kariini N, Rouhani N. COVID-19 and intracerebral haemorrhage: causative or coincidental? Neu Micros Neu Infec. 2020;51:206854.
15. Siegler JE, Cardona P, Arenillas JF, et al. Cerebrovascular events and outcomes in hospitalized patients with COVID-19: the SVIN COVID-19 multinational registry. Int J Stroke. 2021;16:437-447.
16. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2020;200:845-867.
17. Solario-Pineda S, Almendarez-Sanchez CA, Tafur-Grandez AA, et al. Pituitary macroadenoma apoplexy in a severe acute respiratory syndrome-coronavirus-2-positive testing: causal or casual? Surg Neurol Int. 2020;11:304.
18. Chang J, Gregory KD, Smithson SS, Naqui M, Mamelak AN. Pituitary apoplexy associated with acute COVID-19 infection and pregnancy. Pituitary. 2020;23:716-720.
19. Bondes SJ, Phang-Lyn S, Najera E, Borghesi-Razavi H, Adada B. Pituitary apoplexy attributed to COVID-19 infection in the absence of an underlying macroadenoma or other identifiable cause. Cureus. 2021;13:e5355.
20. LaRoy M, McGuire M. Pituitary apoplexy in the setting of COVID-19 infection: a case report [e-pub ahead of print]. Am J Emerg Med. https://doi.org/10.1016/j.ajem.2021.02.045, accessed April 30, 2021.
21. Gosh R, Roy D, Roy D, et al. A rare case of SARS-CoV-2 infection associated with pituitary apoplexy without comorbidities. J Endor Soc 2021; 5:boaa2003.
22. Katti V, Ramanurthy LB, Kanakpur S, Shet SD, Dhoost M. Neuro-ophthalmic presentation of COVID-19 disease: a case report. Indian J Ophthal mol. 2021;69:992-994.
23. Gaudino R, Orlando V, Cavarzere P, et al. Case report: SARS-CoV-2 infection in a child with suprasellar tumor and hypothalamic-pituitary failure. Front Endocrin (Lausanne). 2021;12:596654.
24. Bray DP, Solares CA, Opysika NM. Rare case of a disappearing pituitary adenoma during the coronavirus disease 2019 (COVID-19) pandemic. World Neurosurg. 2021;146:148-149.
25. dos Santos e Santos C, da Costa Lima LM, Santos CAT, Neill JS, Valle HF, Kurnutula LN. Pituitary tumor resection in a patient with SARS-
CoV-2 (COVID-19) infection: a case report and suggested airway management guidelines. Braz J Anesthesiol. 2020;70:169-170.

26. Ricciuti R, Nocchi N, Arnoldi G, Polonara G, Luci M. Pituitary adenoma apoplexy: review of personal series. Asian J Neurosurg. 2018;13:350-354.

27. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72:377-382.

28. Oldfield EH, Merrill MJ. Apoplexy of pituitary adenomas: the perfect storm. J Neurosurg. 2013;121:1444-1449.

29. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wiss JA. Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab. 2000;85:1159-1162.

30. Schecter J, Goldsmith P, Wilson G, Weiner R. Morphological evidence for the presence of arteries in human prolactinomas. J Clin Endocrinol Metab. 1988;67:713-719.

31. Solomon IH, Normandin E, Bhafacharyya S, et al. Neuropathological features of COVID-19. N Engl J Med. 2020;383:e58-e64.

32. Matschke J, Lütgehetmann M, Hagel C, et al. Hypopituitarism after orthohantavirus infection: what is currently known? Viruses. 2019;11:e340.

33. Bhoelan S, Langerak T, Noack D, et al. Hypopituitarism after orthohantavirus infection: what is currently known? Viruses. 2019;11:e340.

34. Tan SK, Seow CJ, Tan E, Chau YP, Dulan E. Pituitary apoplexy secondary to thrombocytopenia due to dengue hemorrhagic fever: a case report and review of the literature. Endocr Pract. 2014;20: e56-e64.

35. Li Y, Li M, Wang M, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020;5:279-284.

36. Yagh Sh, Ishida K, Torres J, et al. SARS-CoV-2 and stroke in a New York healthcare system. Stroke. 2020;51:2002-2011.

37. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:1-14.

38. Keller E, Brandi G, Winklhofer S, et al. Large and small cerebral vessel involvement in severe COVID-19: detailed clinical workup of a case series. Stroke. 2020;51:3779-3782.

39. Divani AA, Andalib S, Biller J, et al. Central nervous system manifestations associated with COVID-19. Curr Neurol Neurosci Rep. 2020;20:60.

40. Chen EC, Zon R, Bajnelli E, Connors J. Approach to the patient with COVID-19-associated thrombosis: a case-based review. Oncologist. 2020;25:e1500-e1508.

41. Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol. 2015;12:14.

42. Nawar RN, AbdelMannan D, Selman WR, Arafah BM. Pituitary tumor apoplexy: a review. J Intensive Care Med. 2008;23:75-90.

43. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782-793.

44. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-coronavirus-2. Infect Dis. 2020;34:55-58.

45. Fang L, Karakulalas M, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lanz Med. 2020;8:521.

46. Kim SH, Lee KC, Kim SH. Cranial nerve palsies accompanying pituitary tumour. J Clin Neurosci. 2007;14:1156-1162.

47. Almeida JP, Sanchez MM, Kakekezi C, et al. Pituitary apoplexy: results of surgical and conservative management clinical series and review of the literature. World Neurosurg. 2019;121:e998-e999.

48. Tang MY, Chen TW, Zhang XM, Huang XH. GRE T2-weighted MRI: principles and clinical applications. Biomed Res Int. 2014;2014:e232142.

49. Fleseriu M, Buchfelder M, Cetas JS, et al. Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective. Pituitary. 2020;23:327-337.

50. Agarwal A, Fernando SM, Honarmand K, et al. Risk of dispersion or aerosol generation and infection transmission with nasopharyngeal and oropharyngeal swabs for detection of COVID-19: a systematic review. BMJ Opm. 2021;11:e040616.